FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300688753> ?p ?o ?g. }

• W4300688753 endingPage "1227" @default.
• W4300688753 startingPage "1227" @default.
• W4300688753 abstract "In 2 trials enrolling patients with heart failure (HF) across the spectrum of ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of worsening HF events or death from cardiovascular (CV) causes.To examine the effects of dapagliflozin on cause-specific CV and non-CV mortality across the spectrum of EF.This was a participant-level, pooled, prespecified secondary analysis of data from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, or DAPA-HF trial (participant left ventricular EF [LVEF] ≤40%), and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure, or DELIVER trial (participant LVEF >40%), to assess the effects of randomized treatment on cause-specific mortality. The trials assigned adjacent populations of patients with chronic HF, New York Heart Association class II-IV symptoms, and elevated natriuretic peptides to treatment with dapagliflozin (10 mg, once daily) or placebo. The primary outcome for each study was a composite of worsening HF events (hospitalization or urgent heart failure visits) or CV death. Clinical outcomes, including all deaths, were adjudicated as to cause by clinical end points committees blinded to treatment assignment.Dapagliflozin vs placebo.The mode of death in relation to baseline EF was examined, as well as the effect of randomized treatment on cause-specific death in Cox regression models. Relationships with continuous EF were modeled using Poisson regression.Of 11 007 patients in the pooled data set, there were 1628 deaths during follow-up (mean [SD] age, 71.7 [10.3] years; 1139 male [70.0%]). Of those who died, 872 (53.5%) were ascribed to CV deaths, 487 (29.9%) to non-CV deaths, and 269 (16.5%) to undetermined causes. Of CV deaths, 289 (33.1%; this represented 17.8% of total deaths) were due to HF, 441 (50.6%; 27.1% of total deaths) were sudden, 69 (7.9%; 4.2% of total deaths) were due to stroke, 47 (5.4%; 2.9% of total deaths) to myocardial infarction, and 26 (3.0%; 1.6% of total deaths) were due to other CV causes. The proportion of non-CV deaths was higher in those with higher EF. In the pooled population, across the spectrum of EF, treatment with dapagliflozin was associated with lower rates of CV death (hazard ratio [HR], 0.86; 95% CI, 0.75-0.98; P = .02), principally due to lower rates of sudden death (HR, 0.84; 95% CI, 0.70-1.01; P = .07) and HF death (HR, 0.88; 95% CI, 0.70-1.11; P = .30), with little difference in rates of death from stroke or MI.In a pooled analysis of patients with HF in the DAPA-HF and DELIVER randomized clinical trials, across the full spectrum of LVEF, dapagliflozin significantly reduced risks of CV death with contributions from lower rates of sudden death and death from progressive HF.ClinicalTrials.gov Identifier: NCT03036124, NCT03619213." @default.
• W4300688753 created "2022-10-04" @default.
• W4300688753 creator A5007021966 @default.
• W4300688753 creator A5009535057 @default.
• W4300688753 creator A5010456790 @default.
• W4300688753 creator A5018432247 @default.
• W4300688753 creator A5029115072 @default.
• W4300688753 creator A5044740469 @default.
• W4300688753 creator A5048450888 @default.
• W4300688753 creator A5049982437 @default.
• W4300688753 creator A5054830306 @default.
• W4300688753 creator A5057759766 @default.
• W4300688753 creator A5058978998 @default.
• W4300688753 creator A5061881316 @default.
• W4300688753 creator A5070122034 @default.
• W4300688753 creator A5080491086 @default.
• W4300688753 creator A5081409622 @default.
• W4300688753 creator A5085961487 @default.
• W4300688753 date "2022-12-01" @default.
• W4300688753 modified "2023-09-30" @default.
• W4300688753 title "Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction" @default.
• W4300688753 cites W2095835518 @default.
• W4300688753 cites W2109051856 @default.
• W4300688753 cites W2582848829 @default.
• W4300688753 cites W2974260792 @default.
• W4300688753 cites W3190779232 @default.
• W4300688753 cites W329648041 @default.
• W4300688753 cites W4226034332 @default.
• W4300688753 cites W4230337229 @default.
• W4300688753 cites W4254537910 @default.
• W4300688753 cites W4293332098 @default.
• W4300688753 cites W4293354639 @default.
• W4300688753 cites W4233207332 @default.
• W4300688753 doi "https://doi.org/10.1001/jamacardio.2022.3736" @default.
• W4300688753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36189985" @default.
• W4300688753 hasPublicationYear "2022" @default.
• W4300688753 type Work @default.
• W4300688753 citedByCount "10" @default.
• W4300688753 countsByYear W43006887532022 @default.
• W4300688753 countsByYear W43006887532023 @default.
• W4300688753 crossrefType "journal-article" @default.
• W4300688753 hasAuthorship W4300688753A5007021966 @default.
• W4300688753 hasAuthorship W4300688753A5009535057 @default.
• W4300688753 hasAuthorship W4300688753A5010456790 @default.
• W4300688753 hasAuthorship W4300688753A5018432247 @default.
• W4300688753 hasAuthorship W4300688753A5029115072 @default.
• W4300688753 hasAuthorship W4300688753A5044740469 @default.
• W4300688753 hasAuthorship W4300688753A5048450888 @default.
• W4300688753 hasAuthorship W4300688753A5049982437 @default.
• W4300688753 hasAuthorship W4300688753A5054830306 @default.
• W4300688753 hasAuthorship W4300688753A5057759766 @default.
• W4300688753 hasAuthorship W4300688753A5058978998 @default.
• W4300688753 hasAuthorship W4300688753A5061881316 @default.
• W4300688753 hasAuthorship W4300688753A5070122034 @default.
• W4300688753 hasAuthorship W4300688753A5080491086 @default.
• W4300688753 hasAuthorship W4300688753A5081409622 @default.
• W4300688753 hasAuthorship W4300688753A5085961487 @default.
• W4300688753 hasBestOaLocation W43006887531 @default.
• W4300688753 hasConcept C126322002 @default.
• W4300688753 hasConcept C134018914 @default.
• W4300688753 hasConcept C142724271 @default.
• W4300688753 hasConcept C164705383 @default.
• W4300688753 hasConcept C203092338 @default.
• W4300688753 hasConcept C204787440 @default.
• W4300688753 hasConcept C27081682 @default.
• W4300688753 hasConcept C2777180221 @default.
• W4300688753 hasConcept C2777422806 @default.
• W4300688753 hasConcept C2778198053 @default.
• W4300688753 hasConcept C2779134260 @default.
• W4300688753 hasConcept C29374701 @default.
• W4300688753 hasConcept C50382708 @default.
• W4300688753 hasConcept C535046627 @default.
• W4300688753 hasConcept C555293320 @default.
• W4300688753 hasConcept C71924100 @default.
• W4300688753 hasConcept C78085059 @default.
• W4300688753 hasConceptScore W4300688753C126322002 @default.
• W4300688753 hasConceptScore W4300688753C134018914 @default.
• W4300688753 hasConceptScore W4300688753C142724271 @default.
• W4300688753 hasConceptScore W4300688753C164705383 @default.
• W4300688753 hasConceptScore W4300688753C203092338 @default.
• W4300688753 hasConceptScore W4300688753C204787440 @default.
• W4300688753 hasConceptScore W4300688753C27081682 @default.
• W4300688753 hasConceptScore W4300688753C2777180221 @default.
• W4300688753 hasConceptScore W4300688753C2777422806 @default.
• W4300688753 hasConceptScore W4300688753C2778198053 @default.
• W4300688753 hasConceptScore W4300688753C2779134260 @default.
• W4300688753 hasConceptScore W4300688753C29374701 @default.
• W4300688753 hasConceptScore W4300688753C50382708 @default.
• W4300688753 hasConceptScore W4300688753C535046627 @default.
• W4300688753 hasConceptScore W4300688753C555293320 @default.
• W4300688753 hasConceptScore W4300688753C71924100 @default.
• W4300688753 hasConceptScore W4300688753C78085059 @default.
• W4300688753 hasIssue "12" @default.
• W4300688753 hasLocation W43006887531 @default.
• W4300688753 hasLocation W43006887532 @default.
• W4300688753 hasLocation W43006887533 @default.
• W4300688753 hasLocation W43006887534 @default.
• W4300688753 hasOpenAccess W4300688753 @default.

• next